| VRAX Stock | | | USD 1.97 0.10 4.83% |
This module uses fundamental data of Virax Biolabs to approximate its Piotroski F score. Virax Biolabs F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Virax Biolabs Group. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Virax Biolabs financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out
Virax Biolabs Altman Z Score,
Virax Biolabs Correlation,
Virax Biolabs Valuation, as well as analyze
Virax Biolabs Alpha and Beta and
Virax Biolabs Hype Analysis.
At this time, Virax Biolabs'
Debt To Equity is fairly stable compared to the past year.
Total Debt To Capitalization is likely to rise to 0.01 in 2024, whereas
Short and Long Term Debt Total is likely to drop slightly above 210.1
K in 2024. At this time, Virax Biolabs'
PTB Ratio is fairly stable compared to the past year.
PB Ratio is likely to rise to 0.29 in 2024, whereas
Price To Sales Ratio is likely to drop 8.96 in 2024.
At this time, it appears that Virax Biolabs' Piotroski F Score is Healthy. Although some professional money managers and academia have recently criticized
Piotroski F-Score model, we still consider it an effective method of
predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
5.0
Piotroski F Score - Healthy
| Change in Return on Assets | |
| Cash Flow Return on Assets | |
| Current Quality of Earnings (accrual) | |
| Long Term Debt Over Assets Change | |
| Change In Outstending Shares | |
Virax Biolabs Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Virax Biolabs is to make sure Virax is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Virax Biolabs' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Virax Biolabs' financial numbers are properly reported.
Virax Biolabs Group F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical
financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Virax Biolabs' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Virax Biolabs in a much-optimized way.
Click cells to compare fundamentals
About Virax Biolabs Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled
Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
About Virax Biolabs Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Virax Biolabs Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Virax Biolabs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at
the intrinsic value of Virax Biolabs Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing
financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our
fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to
measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to
predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.